For research use only. Not for therapeutic Use.
XL388（Cat No.:I000999）is a newly developed compound that exhibits remarkable potency and selectivity as an inhibitor of the mammalian target of rapamycin (mTOR). With an IC50 value of 9.9 nM, it effectively inhibits mTOR activity. XL388 demonstrates a high level of selectivity, being 1000 times more selective towards mTOR compared to closely related PI3K kinases. This selectivity allows for targeted inhibition of mTOR signaling pathways, making XL388 a promising candidate for therapeutic interventions in diseases where dysregulation of mTOR is implicated, such as certain types of cancers and metabolic disorders.
| Catalog Number | I000999 |
| CAS Number | 1251156-08-7 |
| Synonyms | [7-(6-aminopyridin-3-yl)-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]-(3-fluoro-2-methyl-4-methylsulfonylphenyl)methanone |
| Molecular Formula | C23H22FN3O4S |
| Purity | ≥95% |
| Target | Autophagy |
| Solubility | in DMSO > 10 mM |
| Storage | Store at -20°C |
| IC50 | 9.9 nM |
| IUPAC Name | [7-(6-aminopyridin-3-yl)-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]-(3-fluoro-2-methyl-4-methylsulfonylphenyl)methanone |
| InChI | InChI=1S/C23H22FN3O4S/c1-14-18(5-7-20(22(14)24)32(2,29)30)23(28)27-9-10-31-19-6-3-15(11-17(19)13-27)16-4-8-21(25)26-12-16/h3-8,11-12H,9-10,13H2,1-2H3,(H2,25,26) |
| InChIKey | LNFBAYSBVQBKFR-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC(=C1F)S(=O)(=O)C)C(=O)N2CCOC3=C(C2)C=C(C=C3)C4=CN=C(C=C4)N |
| Reference | </br>1:The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent. Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, Fang Z, Shen Z, Ding Q, Chen S.Oncotarget. 2017 May 2;8(18):30151-30161. doi: 10.18632/oncotarget.15620. PMID: 28404914 Free Article</br>2:The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models. Zhu YR, Zhou XZ, Zhu LQ, Yao C, Fang JF, Zhou F, Deng XW, Zhang YQ.Oncotarget. 2016 Aug 2;7(31):49527-49538. doi: 10.18632/oncotarget.10389. PMID: 27385099 Free PMC Article |
